Skip to main content
. 2020 Nov 2;70(5):1277–1289. doi: 10.1007/s00262-020-02750-1

Fig. 1.

Fig. 1

Granzyme B in peripheral blood mononuclear cells (GrB-PBMC) in malignancy and paraneoplastic neurological syndromes (PNS). a Schematic of an experimental procedure to isolate PBMC and measure GrB-PBMC in study groups. b GrB-PBMC in patients with nonmalignant lesions (nonmalignant ovarian tumors and leiomyomas), malignant tumors (collectively ovarian and lung), and PNS. c GrB-PBMC in patients with PNS with and without onconeural antibodies detected in serum. d GrB-PBMC in patients with PNS that clinically affected either the peripheral or central nervous system. e GrB-PBMC in patients with paraneoplastic peripheral neuropathy and paraneoplastic cerebellar degeneration (PCD). The central line corresponds to the median. The upper and lower “hinges” correspond to the first and third quartiles. P values are denoted as asterisks: ns—p > 0.05, *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. A statistical test is specified in the text